PHASE 2 CLINICAL EVALUATION OF PRECLINICALLY DEFINED BIOMARKERS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TYROSINE KINASE INHIBITOR (TKI) TIVOZANIB IN RENAL CELL CARCINOMA (RCC)

被引：0
|
作者：
Hutson, T. [1 ]
Rathmell, W. K. [2 ]
Feng, B. [3 ]
Robinson, M. O. [3 ]
Gyuris, J. [3 ]
Lin, J. [3 ]
Choueiri, T. [4 ]
机构：
[1] Baylor Sammons Canc Ctr, GU Oncol Program, Dallas, TX USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, North Carolina Canc Hosp, Chapel Hill, NC 27599 USA
[3] AVEO Oncol, Clin Res, Cambridge, MA USA
[4] Dana Farber Canc Inst, Div Solid Tumor Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu326.66
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
233P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma
    Chan, Abigail Sy
    Pond, Gregory Russell
    Sonpavde, Guru
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] Expression of vascular endothelial growth factor a (VEGF-A), VEGF receptor 1 (VEGFR-1) and VEGFR-2 in clear cell and papillary renal cell carcinoma (RCC): Implications for therapy
    Leppert, JT
    Lam, JS
    Yu, H
    Seligson, DB
    Dong, J
    Horvath, S
    Pantuck, AJ
    Figlin, RA
    Belldegrun, AS
    JOURNAL OF UROLOGY, 2005, 173 (04): : 362 - 362
  • [43] Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications
    Aslam, Shahzeena
    Eisen, Tim
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2013, 5 (06) : 324 - 333
  • [44] Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)
    Stephenson, J.
    Schreeder, M.
    Waples, J.
    Hargis, J.
    Campos, L.
    Birch, R.
    Henderson, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma
    Mikami, Shuji
    Mizuno, Ryuichi
    Kosaka, Takeo
    Tanaka, Nobuyuki
    Kuroda, Naoto
    Nagashima, Yoji
    Okada, Yasunori
    Oya, Mototsugu
    PATHOLOGY INTERNATIONAL, 2020, 70 (10) : 712 - 723
  • [46] Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma
    Nadal, R.
    Amin, A.
    Geynisman, D. M.
    Voss, M. H.
    Weinstock, M.
    Doyle, J.
    Zhang, Z.
    Viudez, A.
    Plimack, E. R.
    McDermott, D. F.
    Motzer, R.
    Rini, B.
    Hammers, H. J.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1304 - 1311
  • [47] Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials
    Ghatalia, Pooja
    Je, Youjin
    Nguyen, Paul L.
    Quoc-Dien Trinh
    Choueiri, Toni K.
    Sonpavde, Guru
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (02) : 251 - 263
  • [48] Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor
    Mizuno, Ryuichi
    Miyajima, Akira
    Oya, Mototsugu
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (07) : 740 - 740
  • [49] Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors
    Pal, Sumanta K.
    Li, Sierra M.
    Wu, Xiwei
    Qin, Hanjun
    Kortylewski, Marcin
    Hsu, Joann
    Carmichael, Courtney
    Frankel, Paul
    CLINICAL CANCER RESEARCH, 2015, 21 (23) : 5286 - 5293
  • [50] Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor
    Park, Kwonoh
    Lee, Jae-Lyun
    Ahn, Jin-Hee
    Lee, Kyoo Hyung
    Jeong, In-Gab
    Song, Cheryn
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    CANCER RESEARCH AND TREATMENT, 2014, 46 (04): : 339 - 347
12345